Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy QIAGEN N-V stock

Own QIAGEN N-V stock in just a few minutes.

QIAGEN N.V is a diagnostics & research business based in the US. QIAGEN N-V shares (QGEN) are listed on the NYSE and all prices are listed in US Dollars. QIAGEN N-V employs 5,324 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in QIAGEN N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – QGEN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

QIAGEN N-V share price

Use our graph to track the performance of QGEN stocks over time.

QIAGEN N-V shares at a glance

Information last updated 2021-03-10.
52-week range$36.16 - $59.00
50-day moving average $53.06
200-day moving average $51.22
Wall St. target price$59.73
PE ratio 31.1438
Dividend yield N/A (0%)
Earnings per share (TTM) $1.53

Buy QIAGEN N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy QIAGEN N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is QIAGEN N-V under- or over-valued?

Valuing QIAGEN N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of QIAGEN N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

QIAGEN N-V's P/E ratio

QIAGEN N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, QIAGEN N-V shares trade at around 31x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

QIAGEN N-V's PEG ratio

QIAGEN N-V's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.8204. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into QIAGEN N-V's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.


QIAGEN N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $707.2 million.

The EBITDA is a measure of a QIAGEN N-V's overall financial performance and is widely used to measure a its profitability.

QIAGEN N-V financials

Revenue TTM $1.9 billion
Operating margin TTM 27.25%
Gross profit TTM $1.3 billion
Return on assets TTM 5.71%
Return on equity TTM 13.47%
Profit margin 19.2%
Book value $12.27
Market capitalisation $10.9 billion

TTM: trailing 12 months

Shorting QIAGEN N-V shares

There are currently 4.1 million QIAGEN N-V shares held short by investors – that's known as QIAGEN N-V's "short interest". This figure is 2.9% up from 4.0 million last month.

There are a few different ways that this level of interest in shorting QIAGEN N-V shares can be evaluated.

QIAGEN N-V's "short interest ratio" (SIR)

QIAGEN N-V's "short interest ratio" (SIR) is the quantity of QIAGEN N-V shares currently shorted divided by the average quantity of QIAGEN N-V shares traded daily (recently around 963859.71563981). QIAGEN N-V's SIR currently stands at 4.22. In other words for every 100,000 QIAGEN N-V shares traded daily on the market, roughly 4220 shares are currently held short.

However QIAGEN N-V's short interest can also be evaluated against the total number of QIAGEN N-V shares, or, against the total number of tradable QIAGEN N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case QIAGEN N-V's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 QIAGEN N-V shares in existence, roughly 20 shares are currently held short) or 0.0203% of the tradable shares (for every 100,000 tradable QIAGEN N-V shares, roughly 20 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against QIAGEN N-V.

Find out more about how you can short QIAGEN N-V stock.

QIAGEN N-V's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like QIAGEN N-V.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

QIAGEN N-V's total ESG risk score

Total ESG risk: 16.36

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and QIAGEN N-V's overall score of 16.36 (as at 12/31/2018) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like QIAGEN N-V is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

QIAGEN N-V's environmental score

Environmental score: 1.25/100

QIAGEN N-V's environmental score of 1.25 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

QIAGEN N-V's social score

Social score: 8.53/100

QIAGEN N-V's social score of 8.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that QIAGEN N-V is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

QIAGEN N-V's governance score

Governance score: 6.07/100

QIAGEN N-V's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that QIAGEN N-V is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

QIAGEN N-V's controversy score

Controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. QIAGEN N-V scored a 1 out of 5 for controversy – the highest score possible, reflecting that QIAGEN N-V has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

QIAGEN N.V was last rated for ESG on: 2019-01-01.

Total ESG score 16.36
Total ESG percentile 13.68
Environmental score 1.25
Environmental score percentile 2
Social score 8.53
Social score percentile 2
Governance score 6.07
Governance score percentile 2
Level of controversy 1

QIAGEN N-V share dividends

We're not expecting QIAGEN N-V to pay a dividend over the next 12 months.

Have QIAGEN N-V's shares ever split?

QIAGEN N-V's shares were split on a 962:1000 basis on 24 January 2017. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 962 shares. This wouldn't directly have changed the overall worth of your QIAGEN N-V shares – just the quantity. However, indirectly, the new 4% higher share price could have impacted the market appetite for QIAGEN N-V shares which in turn could have impacted QIAGEN N-V's share price.

QIAGEN N-V share price volatility

Over the last 12 months, QIAGEN N-V's shares have ranged in value from as little as $36.16 up to $59. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while QIAGEN N-V's is 0.2839. This would suggest that QIAGEN N-V's shares are less volatile than average (for this exchange).

QIAGEN N-V overview

QIAGEN N. V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels, library prep kits and components, whole genome amplification, etc. ; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site